STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #484 by analyst upside · 2026-06-27
ZURA
Zura Bio Limited
Healthcare · Market Cap $508M · P/E 0x
ANALYST PRICE TARGET
+192.8%
implied upside to consensus target
Current Price $5.35
Consensus Target $15.67
Bull Target $26.0
Bear Target $11.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
0
Sell
0
52-Week Low $1.0
52-Week High $7.44
YTD Return -3.6%
FUNDAMENTALS
Market Cap $508M
P/E Ratio (TTM) N/A
Forward P/E -53.5x
EPS (TTM) $-1.09
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.0
52-Week High $7.44
Current Price $5.35
Bear Target $11.0
Bull Target $26.0
● Now $5.35 ● Target $15.67
TRADING DATA
Avg Volume 794K
YTD Return -3.6%
Analyst Count 6
Consensus Buy
Upside to Target +192.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Zura Bio Limited (ZURA) is currently trading at $5.35 with a Wall Street consensus price target of $15.67, implying potential upside of 192.8% over the next 12 months. 6 analysts currently cover ZURA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $11.0.

ZURA operates in the Healthcare sector with a market capitalisation of $508M. The stock is down 3.6% year-to-date and is currently trading near the upper end of its 52-week range of $1.0 – $7.44.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZURA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital — Reiterated
Buy → Buy 2026-03-23 33% win rate (6 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-03-20 14% win rate (7 calls)
Wedbush ● Initiated
Outperform 2026-02-09 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-11-14 33% win rate (6 calls)
Clear Street ● Initiated
Buy 2025-11-13 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-09-30 33% win rate (6 calls)
HC Wainwright & Co. — Reiterated
Neutral → Neutral 2025-08-19 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2025-08-15 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →